Laboratoire francais, Swedish Orphan Biovitrum sales and marketing update

Swedish Orphan Biovitrum launched LFB's Willfact in Germany to stop and prevent bleeding in patients with severe von Willebrand disease (vWD). The wholesale acquisition cost (WAC) of the plasma-derived von Willebrand factor (vWF) concentrate is €1 per IU. Willfact is dosed at 40 IU/kg twice a week for continuous prophylaxis and 80 IU/kg two-and-a-half times a week to prevent bleeding related to surgery. ...